Inhibition of HIV-1 fusion by either STAg or C-18 is not mediated by production of the β-chemokines MIP-1α and MIP-1β
Inhibitor (dose, μg/mL) . | Antibodies (μg/mL) . | No. of syncytia (% inhibition) PM1/12E1(JR-FL Env) . |
|---|---|---|
| None | None | 305 ± 24 |
| STAg (10) | — | 121 ± 10 (60) |
| αMIP-1α/MIP-1β (2) | 124 ± 2 (59) | |
| C-18 (10) | — | 72 ± 10 (76) |
| αMIP-1α/MIP-1β (2) | 71 ± 12 (77) | |
| MIP-1α + MIP-1β | — | 53 ± 4 (83) |
| αMIP-1α/MIP-1β (2) | 280 ± 32 (8) |
Inhibitor (dose, μg/mL) . | Antibodies (μg/mL) . | No. of syncytia (% inhibition) PM1/12E1(JR-FL Env) . |
|---|---|---|
| None | None | 305 ± 24 |
| STAg (10) | — | 121 ± 10 (60) |
| αMIP-1α/MIP-1β (2) | 124 ± 2 (59) | |
| C-18 (10) | — | 72 ± 10 (76) |
| αMIP-1α/MIP-1β (2) | 71 ± 12 (77) | |
| MIP-1α + MIP-1β | — | 53 ± 4 (83) |
| αMIP-1α/MIP-1β (2) | 280 ± 32 (8) |
— indicates no antibody added.
MIP-1α and MIP-1β (Peprotech). STAg, or C-18 was added to PM1 cells alone or in the presence of αMIP-α/MIP-1β antibodies for 60 minutes at 37°C at the indicated concentrations. Then, 12E1 effector cells (infected overnight with vCB28) were added, and fusion was recorded after 3 to 4 hours.